Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:02 AM
Ignite Modification Date:
2025-12-25 @ 3:02 AM
NCT ID:
NCT02192333
Eligibility Criteria:
Inclusion Criteria:
* Patients enrolled on phase 1 of the study are eligible (and/or if recruited from tumor registry or clinic follow-up schedules)
* Diagnosed with invasive malignancy including: breast, gastrointestinal track, female or male genitourinary system, sarcoma of bone or soft-tissue, leukemia and lymphoma
* Treated at one of the Survivorship Centers of Excellence or their community affiliates
* Received a therapeutic intervention with at least one of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy (any modality)
* Currently between 1.0 and 4.99 years from the completion of active cancer-directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention)
* Patient must still be in active follow-up: seen for a follow-up visit in the participating center at least once in the 3 years prior to enrollment and/or scheduled to be seen for follow-up in the next 6 months (i.e. in active follow-up)
* May be receiving "maintenance" therapy that has a goal of prevention of recurrence but there should be no expectations for further active treatment
* Able to read and speak English adequate to complete the patient-reported outcomes (PRO) assessment
Exclusion Criteria:
* Prior visit to a survivorship clinic or previously provided with a treatment summary and care plan
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
39 Years
Study:
NCT02192333
Study Brief:
Protocol Section:
NCT02192333